# A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

> **NCT06515613** · PHASE1 · RECRUITING · sponsor: **Context Therapeutics Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Platinum-resistant Ovarian Cancer
- Testicular Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** CTIM-76

## Key facts

- **NCT ID:** NCT06515613
- **Lead sponsor:** Context Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06515613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06515613, "A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06515613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*